Patent US4764523A successfully refreshed from Google Patents.
US4764523A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Novel carbonic acid esters
Assignee: Novartis Corp
•
Filing: 1985-12-13
•
Granted: 1988-08-16
•
Expires: 2005-12-13
Abstract
Abstract N- and/or O-acylates, derived from carbonic acid monoesters, of desferrioxamine B of the formula ##STR1## the symbols having the following meanings: each of AA 1 , AA 2 and AA 3 , independently of the others, is hydrogen, an acyl radical, referred to as Ac, of a carboxylic acid having from 1 to 24 carbon atoms, or an esterified oxycarbonyl radical referred to as Cb (acyl radical of a carbonic acid monoester) having a total of from 2 to 25 carbon atoms, and B has one of the meanings of Cb or, if at least one of the symbols AA 1 , AA 2 and AA 3 represents Cb, it may also be hydrogen or an amino-protecting group referred to as X, form strong iron (III) and aluminum complexes within living cells and can therefore be used therapeutically for the treatment of warm-blooded animals, including humans, for pathological conditions associated with an excess of iron (III) or aluminum in the body or caused by iron (III)-dependent pathogenic organisms; they can also be used as intermediates for the manufacture of therapeutically effective derivatives of desferrioxamine B. The compounds according to the invention can be obtained by conventional acylation of the free amino group and/or hydroxy groups in desferrioxamine B or a suitable derivative thereof using a chloroformic ester or a similar reactive carbonic acid derivative.
Inventors
- 👤 Heinrich Peter
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 06:07
CPC Classifications
C; C07; C07C; C07C237/00; C07C237/02; C07C237/04; C07C237/06; A; A61; A61K; A61K31/00; A61K31/16
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
90 words
An acylate of desferrioxamine B of the formula ##STR5## wherein at least one of the radicals AA 1 , AA 2 , AA 3 and B is tert.-butyloxycarbonyl, allyloxycarbonyl, 2-(trimethylsilyl)-ethoxycarbonyl or a radical of the formula lower alkyl(--O--CH 2 --CH 2 --) n O--CO-- wherein n represents 1 to 4, and each of the remaining radicals AA 1 , AA 2 , AA 3 and B, independently of the others, represents alkanoyl having up to 20 carbon atoms, benzoyl or hydrogen, or a salt of said acylate having salt-forming properties.
Claim 2
Dependent Claim
90 words
An acylate of desferrioxamine B of the formula ##STR5## wherein at least one of the radicals AA 1 , AA 2 , AA 3 and B is tert.-butyloxycarbonyl, allyloxycarbonyl, 2-(trimethylsilyl)-ethoxycarbonyl or a radical of the formula lower alkyl(--O--CH 2 --CH 2 --) n O--CO-- wherein n represents 1 to 4, and each of the remaining radicals AA 1 , AA 2 , AA 3 and B, independently of the others, represents alkanoyl having up to 20 carbon atoms, benzoyl or hydrogen, or a salt of said acylate having salt-forming properties.
Claim 3
Dependent Claim
77 words
A compound according to claim 1 wherein at least one of the radicals AA 1 , AA 2 , AA 3 and B is tert.-butyloxycarbonyl, allyloxycarbonyl, 2-(trimethylsilyl)-ethoxycarbonyl or a radical of the formula lower alkyl(--O--CH 2 --CH 2 --) n O--CO-- wherein n represents 1 to 4 and each of the remaining radicals AA 1 , AA 2 , AA 3 and B, independently of the others, represents alkanoyl having up to 20 carbon atoms or benzoyl.
Claim 4
Dependent Claim
55 words
A compound according to claim 1 wherein B is hydrogen and each of the radicals AA 1 , AA 2 and AA 3 is tert.-butyloxycarbonyl, allyloxycarbonyl, 2-(trimethysilyl)-ethoxycarbonyl or a radical of the formula lower alkyl(--O--CH 2 --CH 2 --) n O--CO-- wherein n represents 1 to 4, or a pharmaceutically acceptable acid addition salt thereof.
Claim 5
Dependent Claim
47 words
A compound according to claim 1 wherein B is tert.-butyloxycarbonyl, allyloxycarbonyl, 2-(trimethylsilyl)-ethoxycarbonyl or a radical of the formula lower alkyl(--O--CH 2 --CH 2 --) n O--CH-- wherein n represents 1 to 4, and each of the radicals AA 1 , AA 2 and AA 3 represents hydrogen.
Claim 6
Dependent Claim
41 words
A compound according to claim 1 wherein B is tert.-butyloxycarbonyl and each of AA 1 , AA 2 and AA 3 is a radical of the formula lower alkyl(--O--CH 2 --CH 2 --) n O--CO-- wherein n represents 1 to 4.
Claim 7
Dependent Claim
49 words
A compound according to claim 1 wherein B is hydrogen and each of AA 1 , AA 2 and AA 3 is a radical of the formula lower alkyl(--O--CH 2 --CH 2 --) n O--CO-- wherein n represents 1 to 4, or a pharmaceutically acceptable acid addition salt thereof.
Claim 8
Dependent Claim
23 words
A compound according to claim 1 wherein B is tert.-butyloxy-carbonyl and each of AA 1 , AA 2 and AA 3 is 2-methoxyethoxycarbonyl.
Claim 9
Dependent Claim
23 words
A compound according to claim 1 wherein B is tert.-butyloxycarbonyl and each of AA 1 , AA 2 and AA 3 is 2-(2-methoxyethoxy)-ethoxycarbonyl.
Claim 10
Dependent Claim
23 words
A compound according to claim 1 wherein B is tert.-butyloxy-carbonyl and each of AA 1 , AA 2 and AA 3 is n-octanoyl.
Claim 11
Dependent Claim
31 words
A compound according to claim 1 wherein B is hydrogen and each of AA 1 , AA 2 and AA 3 is 2-methoxyethoxycarbonyl, or a pharmaceutically acceptable acid addition salt thereof.
Claim 12
Dependent Claim
31 words
A compound according to claim 1 wherein B is hydrogen and each of AA 1 , AA 2 and AA 3 is 2-(2-methoxy-ethoxy)-ethoxycarbonyl, or a pharmaceutically acceptable acid addition salt thereof.
Claim 13
Dependent Claim
52 words
A pharmaceutical composition for the prophylaxis or treatment of pathological conditions associated with an excess of iron(III) or aluminium or caused by iron(III)-dependent microorganism in a warm-blooded animal comprising as the active ingredient a prophylactically or therapeutically effective amount of a compound as claimed in claim 1 and a pharmaceutically acceptable carrier.
Claim 14
Dependent Claim
62 words
A pharmaceutical composition for oral administration to a warm-blooded animal in the form of a tablet, a dragee or capsule for the prophylaxis or treatment of a pathological condition associated with an excess of iron(III) or aluminium or caused by an iron(III)-dependent microorganism comprising as the active ingredient a prophylactically or therapeutically effective amount of a compound as claimed in claim 2.
Claim 15
Dependent Claim
55 words
A method for the prophylaxis or treatment of a warm-blooded animal, for pathological conditions associated with an excess of iron(III) or aluminium in the body, comprising orally administering to said animal a prophylactically or therapeutically effective amount of a compound according to claim 2 on its own or in the form of a pharmaceutical composition.
Claim 16
Dependent Claim
48 words
A method for the prophylaxis or treatment of a warm-blooded animal for pathological conditions caused by iron(III)-dependent microorganisms, comprising orally administering to said animal a prophylactically or therapeutically effective amount of a compound according to claim 2 on its own or in the form of a pharmaceutical composition.
Claim 17
Dependent Claim
2 words
N,O,O'O"-tetra-desferrioxamine B.
Claim 18
Dependent Claim
2 words
N,O,O'O"-tetra-desferrioxamine B.
Claim 19
Dependent Claim
10 words
O,O',O"-tri-desferrioxamine B or a pharmaceutically acceptable acid addition salt thereof.
Claim 20
Dependent Claim
10 words
O,O',O"-tri-desferrioxamine B or a pharmaceutically acceptable acid addition salt thereof.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-08-16 | 1992-02-15 | 1992-08-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-08-16 | 1996-02-15 | 1996-08-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-08-16 | 2000-02-15 | 2000-08-16 | $7700.00 | Window Closed / Lapsed |